Bruker (BRKR) said Thursday that it has agreed to a final settlement with 10x Genomics (TXG) to resolve their patent disputes and dismiss multiple lawsuits.
Under the settlement, all ongoing lawsuits and administrative proceedings filed by both companies will be withdrawn, including litigation pending in the US, Germany, and the European Unified Patent Court.
Financial terms were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.